-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to data from Flush, as of April 12, 2022, the stock prices of many pharmaceutical stocks such as Kangyuan Pharmaceutical, China Resources Shuanghe, Dali Pharmaceutical, and First Medicine have reached a new high in one year
.
Kangyuan Pharmaceutical As of April 12, 2022, Kangyuan Pharmaceutical increased by 0.
87%, with a turnover rate of 8.
42%, and the new price was 16.
18 yuan.
The previous high date was on April 11, 2022, and the previous high was 16.
04
.
The stock price has hit a new high since November 2019, up 6.
4%, and has risen about 40% during the year
.
The company's first-quarter report shows that from January to March 2022, the operating income was 1.
079 billion yuan, a year-on-year increase of 25.
16%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 30.
94%
.
Among them, the operating income of injections increased by 40.
47% compared with the same period of the previous year, and the operating costs increased by 36.
69% compared with the same period of the previous year, mainly due to the year-on-year increase in sales of Reduning injections
.
The operating income of oral liquid increased by 69.
34% compared with the same period of the previous year, and the operating cost increased by 63.
48% compared with the same period of the previous year, mainly due to the year-on-year increase in the sales of Jinzhen oral liquid
.
According to the data, Kangyuan Pharmaceutical is a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales.
For the two-wing development system
.
As of April 12, 2022, as of April 12, 2022, China Resources Shuanghe increased by 7.
29%, the turnover rate was 9.
35%, and the new price was 17.
37 yuan.
The previous high point date was March 31, 2022.
The previous high was 17
.
According to the 2021 annual report released by China Resources Shuanghe on the evening of March 24, the operating income in 2021 will be about 9.
112 billion yuan, a year-on-year increase of 7.
14%; the net profit attributable to shareholders of the listed company is about 936 million yuan, a year-on-year decrease of 6.
91%; The profit was 0.
8969 yuan, a year-on-year decrease of 6.
91%
.
According to the data, CR Double-Crane adheres to the corporate mission of "caring for the public, healthy people's livelihood", focusing on the future, and has built three major business platforms: chronic disease business, specialist business and infusion business
.
Dali Pharmaceutical As of April 12, 2022, Dali Pharmaceutical's increase was 10.
00%, the turnover rate was 11.
83%, and the new price was 15.
62 yuan.
The previous high date was on April 11, 2022, and the previous high was 14.
20
.
It is reported that since March 1, the stock price of Dali Pharmaceutical has been rising all the way.
As of April 11, the stock price has increased by as much as 89.
84%, and a total of 10 daily limits have been achieved.
From March 2 to March 7, and from April 6 to April There are 4 consecutive boards in the 11-day interval
.
The company's annual performance forecast shows that it is expected that the net profit attributable to shareholders of the listed company will be -45 million yuan to -40 million yuan in 2021, compared with the net profit in 2020
.
According to the financial report, Dali Pharmaceutical is mainly engaged in the production and sales of Chinese and Western medicine injections.
Its core products include Xingnaojing Injection and Shenmai Injection
.
Among them, Xingnaojing injection is a drug for cerebrovascular diseases, which belongs to the category B product of Chinese patent medicine under the national medical insurance; Shenmai injection is a drug for cardiovascular disease, which belongs to the category of the national essential medicine list and a category A product of the national medical insurance Chinese patent medicine
.
As of April 12, 2022, First Medicine had an increase of 10.
02%, a turnover rate of 24.
39%, and a new quotation of 14.
28 yuan.
The previous high date was on April 11, 2022, and the previous high was 12.
98
.
First Medicine released its 2021 annual report on the evening of April 1, saying that in 2021, its operating income will be about 1.
398 billion yuan, a year-on-year decrease of 11.
89%; the net profit attributable to shareholders of listed companies is about 49.
42 million yuan, a year-on-year decrease of 27.
9%; basic earnings per share 0.
22 yuan, a year-on-year decrease of 29.
03%
.
According to the data, the main business of First Pharmaceutical is the distribution of chemical raw materials, chemical preparations, biological products, Chinese and Western medicines, and department stores
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Kangyuan Pharmaceutical As of April 12, 2022, Kangyuan Pharmaceutical increased by 0.
87%, with a turnover rate of 8.
42%, and the new price was 16.
18 yuan.
The previous high date was on April 11, 2022, and the previous high was 16.
04
.
The stock price has hit a new high since November 2019, up 6.
4%, and has risen about 40% during the year
.
The company's first-quarter report shows that from January to March 2022, the operating income was 1.
079 billion yuan, a year-on-year increase of 25.
16%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 30.
94%
.
Among them, the operating income of injections increased by 40.
47% compared with the same period of the previous year, and the operating costs increased by 36.
69% compared with the same period of the previous year, mainly due to the year-on-year increase in sales of Reduning injections
.
The operating income of oral liquid increased by 69.
34% compared with the same period of the previous year, and the operating cost increased by 63.
48% compared with the same period of the previous year, mainly due to the year-on-year increase in the sales of Jinzhen oral liquid
.
According to the data, Kangyuan Pharmaceutical is a large-scale traditional Chinese medicine enterprise integrating drug research and development, production and sales.
For the two-wing development system
.
As of April 12, 2022, as of April 12, 2022, China Resources Shuanghe increased by 7.
29%, the turnover rate was 9.
35%, and the new price was 17.
37 yuan.
The previous high point date was March 31, 2022.
The previous high was 17
.
According to the 2021 annual report released by China Resources Shuanghe on the evening of March 24, the operating income in 2021 will be about 9.
112 billion yuan, a year-on-year increase of 7.
14%; the net profit attributable to shareholders of the listed company is about 936 million yuan, a year-on-year decrease of 6.
91%; The profit was 0.
8969 yuan, a year-on-year decrease of 6.
91%
.
According to the data, CR Double-Crane adheres to the corporate mission of "caring for the public, healthy people's livelihood", focusing on the future, and has built three major business platforms: chronic disease business, specialist business and infusion business
.
Dali Pharmaceutical As of April 12, 2022, Dali Pharmaceutical's increase was 10.
00%, the turnover rate was 11.
83%, and the new price was 15.
62 yuan.
The previous high date was on April 11, 2022, and the previous high was 14.
20
.
It is reported that since March 1, the stock price of Dali Pharmaceutical has been rising all the way.
As of April 11, the stock price has increased by as much as 89.
84%, and a total of 10 daily limits have been achieved.
From March 2 to March 7, and from April 6 to April There are 4 consecutive boards in the 11-day interval
.
The company's annual performance forecast shows that it is expected that the net profit attributable to shareholders of the listed company will be -45 million yuan to -40 million yuan in 2021, compared with the net profit in 2020
.
According to the financial report, Dali Pharmaceutical is mainly engaged in the production and sales of Chinese and Western medicine injections.
Its core products include Xingnaojing Injection and Shenmai Injection
.
Among them, Xingnaojing injection is a drug for cerebrovascular diseases, which belongs to the category B product of Chinese patent medicine under the national medical insurance; Shenmai injection is a drug for cardiovascular disease, which belongs to the category of the national essential medicine list and a category A product of the national medical insurance Chinese patent medicine
.
As of April 12, 2022, First Medicine had an increase of 10.
02%, a turnover rate of 24.
39%, and a new quotation of 14.
28 yuan.
The previous high date was on April 11, 2022, and the previous high was 12.
98
.
First Medicine released its 2021 annual report on the evening of April 1, saying that in 2021, its operating income will be about 1.
398 billion yuan, a year-on-year decrease of 11.
89%; the net profit attributable to shareholders of listed companies is about 49.
42 million yuan, a year-on-year decrease of 27.
9%; basic earnings per share 0.
22 yuan, a year-on-year decrease of 29.
03%
.
According to the data, the main business of First Pharmaceutical is the distribution of chemical raw materials, chemical preparations, biological products, Chinese and Western medicines, and department stores
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
